Biallelic Inactivation of <i>BRCA2</i> in Fanconi Anemia

Niall G. Howlett(Dana-Farber Cancer Institute), Toshiyasu Taniguchi(Dana-Farber Cancer Institute), Susan B. Olson(Oregon Health & Science University), Barbara Cox(Oregon Health & Science University), Quinten Waisfisz, Christine de Die‐Smulders(Maastricht University Medical Centre), Nicole S. Persky(Dana-Farber Cancer Institute), Markus Grompe(Oregon Health & Science University), Hans Joenje, Gerard Pals, Hideyuki Ikeda(Sapporo Medical University), Edward A. Fox(Dana-Farber Cancer Institute), Alan D. D’Andrea(Dana-Farber Cancer Institute)
Science
July 26, 2002
Cited by 1,140

Abstract

Fanconi anemia (FA) is a rare autosomal recessive cancer susceptibility disorder characterized by cellular hypersensitivity to mitomycin C (MMC). Six FA genes have been cloned, but the gene or genes corresponding to FA subtypes B and D1 remain unidentified. Here we show that cell lines derived from FA-B and FA-D1 patients have biallelic mutations in BRCA2 and express truncated BRCA2 proteins. Functional complementation of FA-D1 fibroblasts with wild-type BRCA2 complementary DNA restores MMC resistance. Our results link the six cloned FA genes with BRCA1 and BRCA2 in a common pathway. Germ-line mutation of genes in this pathway may result in cancer risks similar to those observed in families with BRCA1 or BRCA2 mutations.


Related Papers

No related papers found

Powered by citation graph analysis